Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 3
1994 5
1995 8
1996 3
1997 3
1998 3
1999 9
2000 3
2001 4
2002 3
2003 1
2004 3
2005 7
2006 2
2007 6
2009 2
2010 4
2011 4
2012 1
2013 7
2014 1
2015 1
2016 1
2018 1
2019 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

86 results
Results by year
Filters applied: . Clear all
Page 1
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Among authors: rigas jr. Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6. Lancet Oncol. 2016. PMID: 27283860 Free PMC article. Clinical Trial.
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK. Marinis F, et al. Among authors: rigas jr. Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24. Future Oncol. 2019. PMID: 31339357
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators. Deitcher SR, et al. Among authors: rigas jr. Clin Appl Thromb Hemost. 2006 Oct;12(4):389-96. doi: 10.1177/1076029606293692. Clin Appl Thromb Hemost. 2006. PMID: 17000884 Free article. Clinical Trial.
Pemetrexed in advanced non-small-cell lung cancer.
Fuld AD, Dragnev KH, Rigas JR. Fuld AD, et al. Among authors: rigas jr. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560. Expert Opin Pharmacother. 2010. PMID: 20446853 Review.
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.
Schabath MB, Dalvi TB, Dai HA, Crim AL, Midha A, Shire N, Gimbrone NT, Walker J, Greenawalt DM, Lawrence D, Rigas JR, Brody R, Potter D, Kumar NS, Huntsman SA, Gray JE. Schabath MB, et al. Among authors: rigas jr. Cancer Manag Res. 2019 Nov 7;11:9469-9481. doi: 10.2147/CMAR.S218635. eCollection 2019. Cancer Manag Res. 2019. PMID: 31819612 Free PMC article.
Nonclassical retinoids and lung carcinogenesis.
Dragnev KH, Petty WJ, Ma Y, Rigas JR, Dmitrovsky E. Dragnev KH, et al. Among authors: rigas jr. Clin Lung Cancer. 2005 Jan;6(4):237-44. doi: 10.3816/CLC.2005.n.003. Clin Lung Cancer. 2005. PMID: 15694016 Review.
Docetaxel in the treatment of esophageal cancer.
Rigas JR, Dragnev KH, Bubis JA. Rigas JR, et al. Semin Oncol. 2005 Apr;32(2 Suppl 4):S39-51. doi: 10.1053/j.seminoncol.2005.04.005. Semin Oncol. 2005. PMID: 16015553 Review.
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. Bayliss TJ, et al. Among authors: rigas jr. Expert Opin Biol Ther. 2011 Dec;11(12):1663-8. doi: 10.1517/14712598.2011.627850. Epub 2011 Oct 13. Expert Opin Biol Ther. 2011. PMID: 21995322 Review.
The retinoids and cancer prevention mechanisms.
Dragnev KH, Rigas JR, Dmitrovsky E. Dragnev KH, et al. Among authors: rigas jr. Oncologist. 2000;5(5):361-8. doi: 10.1634/theoncologist.5-5-361. Oncologist. 2000. PMID: 11040271 Free article. Review.
86 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page